Autopsy report · NCT00825266

Insulin Resistance in Pulmonary Arterial Hypertension

“difficulty in finding eligible subjects”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months after it had already started.
• Ran for about 1 year 8 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 6 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Stanford University

Sponsor type

University, hospital or other

Conditions

Hypertension, Pulmonary

Interventions

bosentan; Pioglitazone

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema
  “Difficulty enrolling eligible subjects” (84% match in meaning)
• Effect of Externally Implantable Tissue Expansion Device on Scar Length
  “Inability to recruit eligible subjects” (80% match in meaning)
• Effects of Psilocybin in Concussion Headache
  “Challenging to recruit qualifying subjects” (76% match in meaning)
• Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?
  “Difficulty in identifying subjects satisfying the inclusion criteria.” (76% match in meaning)
• Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
  “Lack of eligible subjects.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.